Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

82 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-07-25

Study Completion Date

2006-07-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Participants on immunosuppressive therapy, e.g., organ recipients, had higher occurrence of AK (Actinic Keratosis) than the untreated population. Keratotic lesions (i.e., AK lesions and warts) in this population were highly associated with development of SCC (Squamous Cell Carcinoma) also with 10 times higher mortality rate because of SCC than expected. The risk of developing skin cancer, predominantly SCC and BCC (Basal Cell Carcinoma), increased with graft survival time and the length of immunosuppressive treatment period.

The higher risk of developing skin malignancy and more aggressive skin malignancies in this population, indicated the need for early removal of these pre-malignant lesions.

In this study, two contralateral areas (5x10 cm\^2) with skin lesions within the participant were compared. One area was received Metvix PDT at defined intervals and the other was received lesion specific treatment at the discretion of the investigator. The primary endpoint was the accumulated number of new lesions during the study and number of AK lesions that showed complete response 3 months after baseline. Secondary endpoints were number of BCC lesions that showed complete response, number of recurrent lesions, assessment of cosmetic outcome and safety.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma

NCT00472043

Basal Cell Carcinoma

COMPLETED PHASE3

ADL-PDT Under Routine Clinical Conditions in Patients With Actinic Keratosis

NCT05725213

Actinic Keratoses

COMPLETED

Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Cell Carcinoma

NCT00472108

Basal Cell Carcinoma

COMPLETED PHASE3

Intra-individual Comparison of Efficacy and Safety of Metvix® Natural Daylight Photodynamic Therapy Versus Conventional Metvix® Photodynamic Therapy in Subject With Mild Actinic Keratoses

NCT01475071

Actinic Keratoses

COMPLETED PHASE3

Metvix Daylight PDT in Actinic Keratosis

NCT02674048

Actinic Keratosis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The treatment area (5x10 cm\^2) was treated at baseline and at 3 ,9 and 15 months visits. At baseline, the area was treated with fractionated Metvix® PDT treatment consisting of two treatment one week apart and at 3 ,9 and 15 months visits with single Metvix® PDT treatment. The participants were evaluated for occurrence of new lesions, lesion response and recurrence at 3 (not recurrence),9,15,21, and 27 months visits. New and recurrent lesions in the treated area were treated with Metvix® PDT treatment. Lesions with partial response in the treated area were re-treated with Metvix® PDT and lesions with no response were treated with lesion specific treatment at the discretion of the investigator.

In the contralateral control area (5x10 cm\^2), new and recurrent lesions and lesions in non-complete response were treated with lesion specific treatment at the discretion of the investigator at each study visit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Actinic Keratosis Warts Basal Cell Carcinoma Bowens Disease Squamous Cell Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Metvix®-PDT (Treatment Area +Contralateral Control Area)

Two contralateral areas (symmetrically) were identified with an area of 5\*10-centimeter square, that is (i.e.), treatment and control area. Treatment area was treated with Metvix®-photodynamic therapy (PDT) 160 milligrams/gram (mg/g) cream, given as fractioned regimen consisting of two treatments one week apart on Weeks 0 and Week 1, additional single treatments were given at Months 3, 9, 15, 21 and 27. The contralateral control area was treated using lesion-specific treatment in accordance with the Investigator's preference (example, cryotherapy) at months 3, 9, 15, 21 and 27.

Group Type EXPERIMENTAL

Photodynamic therapy with Metvix 160 mg/g cream

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Photodynamic therapy with Metvix 160 mg/g cream

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Transplant recipients with at least 2 clinically diagnosed AK lesion and maximum 10 skin lesions (AK, BCC, SCC in situ and/or warts) in each of the two contralateral areas (diameter 5x10\^2 cm) in the face, the scalp, the extremities or on the trunk/neck.
* Transplant recipients who previously were treated more than once for their skin lesions.
* Transplant recipients who had received immunosuppressive therapy for more than 3 years.
* Males or females above 18 years of age.
* Written informed consent.

Exclusion Criteria

* Participants with more than 10 skin lesions (AK, BCC, SCC in situ, warts) in one of the two areas.
* Participants with SCC (not SCC in situ) in one of the two areas.
* Participants not previously treated or treated only once for their skin lesions.
* Participants with rosacea in one of the two areas.
* Participants with morphea form/highly infiltrating BCC
* Known allergy to methyl-amino levulinate, a similar compound or excipients of the cream
* Participation in other clinical studies either concurrently or within the last 30 days.
* Pregnant or breast-feeding (all women of child-bearing potential documented a negative pregnancy test and used the pill or IUD during the treatments and for at least one month thereafter).
* Conditions associated with a risk of poor protocol compliance

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No